Ventana, Bayer collaborate on ADC diagnostic test
TUSCON, Ariz.—Ventana Medical Systems Inc. and Bayer Pharma AG have joined forces to develop a molecular companion diagnostic test to identify patients that are most likely to benefit from Bayer's antibody-drug conjugate, or ADC, cancer therapy. Per the agreement, Ventana will use its technology to analyze expression levels in certain tumor targets serving as biomarkers in clinical studies and will be responsible for developing, manufacturing and commercializing a test for one of Bayer's ADC drugs. For up to five years, either company can initiate further projects to develop diagnostic tests for additional cancer therapy drugs. Financial terms were not disclosed.
"As new biomarkers and diagnostic tests become increasingly available, they provide valuable information about potential positive recipients for these novel agents," Mara Aspinall, president of Ventana, said in a press release.